R&D channel feed – Endpoints News

R&D channel feed

Novartis-backed Gamida Cell grabs a breakthrough trophy for experimental cell treatment

9 years ago

Supernus gets a (temporary) boost as ADHD drug clears PhIIb hurdle

9 years ago

Deaths, accusations of insider trading and an early warning from Boehringer stir Hanmi controversy

9 years ago

GSK attempts to remake itself in China with local ties

9 years ago

Takeda adds a $790M discovery deal to an ongoing R&D overhaul

9 years ago

Merck’s glorious victory in lung cancer marks a Russian winter for Bristol-Myers

9 years ago

Novartis heads to the finish line with CDK 4/6 blockbuster contender ribociclib

9 years ago

Tesaro makes its case for a clean sweep with niraparib - and shares soar again

9 years ago

Clovis shares tank after investors size up the disappointing data on rucaparib

9 years ago

Updated Incyte combo data for epacadostat/Keytruda look promising

9 years ago

Lethal experimental cancer drug from Hanmi, Boehringer killed three patients — report

9 years ago

Teva hands Celltrion $160M to grab US rights on two biosimilars of Roche blockbusters

9 years ago

Pilot project provides a snapshot of effectiveness of Pfizer’s PARP contender talazoparib

9 years ago

Feds help NewLink, Merck out with some added cash for Ebola vaccine

9 years ago

Alnylam shares crater after trial deaths force investigators to scrap PhIII RNAi drug

9 years ago

AstraZeneca jettisons another drug, this time grabbing $30M for out-licensing deal

9 years ago

Hold the applause: Big Pharma has little to brag about regarding 2016 R&D productivity

9 years ago

Novartis unveils a new global R&D structure, creating centers in Cambridge, MA and Basel

9 years ago

Novartis is uprooting another research group in ongoing global reorganization

9 years ago

Hustling to capture top frontline NSCLC status, Roche scores a ‘breakthrough’ on Alecensa

9 years ago

Amgen joins a marquee list of partners jumping on Nuevolution’s discovery platform

9 years ago

Soriot’s $3.5B Brilinta dream is dashed by yet another big trial flop for AstraZeneca

9 years ago

Summit shares rocket up, fueled by an $842M pact with Duchenne leader Sarepta

9 years ago

Sun Pharma takes aim at a crowded market with another IL-23 psoriasis drug from Merck

9 years ago

First page Previous page 316 317 318319320 321 322 Next page Last page